Related Experiment Video

Updated: Oct 31, 2025

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids
09:43

Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids

Published on: October 14, 2019

6.7K

Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours

Mohammed Dawod1, Teresa Alonso Gordoa2, Mauro Cives3

  • 1Department of Medical Oncology, ENETs, Centre of Excellence, The Christie NHS Foundation Trust, Manchester, UK.

Current Treatment Options in Oncology
|June 29, 2021
PubMed
Abstract

Insights

This review covers systemic therapies for advanced small bowel neuroendocrine tumors (SBNETs), including somatostatin analogues, PRRT, mTOR inhibitors, and novel tyrosine kinase inhibitors (TKIs). It discusses current guidelines for palliative care in SBNET management.

Area of Science:

  • Oncology
  • Gastroenterology

Background:

  • Neuroendocrine neoplasms (NENs) are increasingly diagnosed, with small bowel neuroendocrine tumors (SBNETs) showing variable outcomes.
  • Treatment efficacy for SBNETs depends on grade, differentiation, tumor burden, and origin, necessitating a multidisciplinary approach.

Purpose of the Study:

  • To provide a comprehensive review of systemic therapeutic options for advanced SBNETs.
  • To discuss current guideline recommendations for palliative treatment of SBNETs.

Main Methods:

  • Review of large randomized clinical trials (PROMID, CLARINET, NETTER-1, RADIANT).
  • Analysis of established and novel systemic therapies including somatostatin analogues, peptide receptor radionuclide therapy (PRRT), mTOR inhibitors, and tyrosine kinase inhibitors (TKIs).

Main Results:

  • Somatostatin analogues, PRRT, and everolimus (mTOR inhibitor) are established treatments for unresectable grade 1 and 2 SBNETs.
  • Tyrosine kinase inhibitors (TKIs) represent emerging therapies.
  • Despite advances, several therapeutic questions for SBNETs remain unresolved.

Conclusions:

  • Systemic therapies have significantly advanced SBNET management, with ongoing research into novel agents like TKIs.
  • A multidisciplinary strategy and adherence to updated guidelines are crucial for optimizing palliative care in advanced SBNETs.
Keywords:
PRRTProgressionSmall bowel neuroendocrine tumourSomatostatin analogueThird-line treatmentWell-differentiated

More Related Videos

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.0K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
317
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K